Tesamorelin Information & Coordination for Licensed U.S. Clinics
Phoenix Meds Inc. provides administrative coordination for licensed U.S. clinics, medical directors, and healthcare organizations reviewing tesamorelin-related product documentation and regulatory information.
For clinic teams, the work often goes beyond identifying a product by name. Credentials need to be reviewed, product information should match the supporting documentation, regulatory records need to be current, and questions between the parties involved need to be resolved without adding unnecessary work for clinical staff.
Phoenix helps organize that process.
Our role includes clinic credential review, documentation support, publicly available regulatory research, product-identity review, and administrative communication with appropriately licensed parties.
Phoenix Meds Inc. does not prescribe, manufacture, compound, dispense, sell, distribute, ship, or take custody of medications.
What Clinics Should Know About Tesamorelin
Tesamorelin is a growth hormone-releasing factor analog and is the proper name associated with FDA-licensed EGRIFTA biological products.
FDA’s Purple Book currently lists EGRIFTA SV 2 mg and EGRIFTA WR 11.6 mg as prescription biological products under BLA 022505. Both are licensed under section 351(a) of the Public Health Service Act.
Current EGRIFTA WR labeling indicates the product for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. The labeling also states that EGRIFTA WR is not indicated for weight-loss management and that its long-term cardiovascular safety has not been established.
For clinics, the practical issue is product identity. A vial, listing, or document that says only “tesamorelin” does not by itself establish that the product is EGRIFTA or carries the regulatory status of an FDA-licensed EGRIFTA product.
That is where careful documentation review matters.
Current FDA and Regulatory Status
EGRIFTA SV and EGRIFTA WR are FDA-licensed biological products under BLA 022505. FDA’s Purple Book identifies both as 351(a) biological products.
That status is important when tesamorelin is discussed in a compounding context. FDA states that biological products subject to section 351 licensure are not eligible for the compounded-drug exemptions under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act.
FDA has separate guidance describing limited circumstances in which an already licensed biological product may be mixed, diluted, or repackaged outside its approved labeling. FDA states that this policy concerns licensed biological products and does not extend to producing the biological product from bulk drug substance.
For clinic administrators, the takeaway is practical: the actual product and its supporting documentation need to be identified before conclusions are drawn about its regulatory status.
Phoenix helps organize that administrative review and directs unresolved product or regulatory questions to the parties responsible for addressing them.
Product Identity & Documentation
FDA currently lists EGRIFTA SV as 2 mg per vial and EGRIFTA WR as 11.6 mg per vial. EGRIFTA WR labeling also states that EGRIFTA WR and EGRIFTA SV have different dosage, preparation, and storage requirements and are not substitutable.
That becomes relevant when a clinic encounters a product described simply as “tesamorelin” or by another strength.
A product name or advertised vial strength alone does not establish that the product is EGRIFTA.
Phoenix helps organize the available product information and supporting records so clinic teams can identify discrepancies or questions that need to be addressed by the responsible licensed party.
We do not independently certify product authenticity, sterility, potency, clinical suitability, or regulatory status.
How Phoenix Meds Supports Tesamorelin Coordination
A sourcing request can involve several administrative checkpoints before the responsible licensed parties determine how to proceed.
Phoenix helps keep those pieces organized.
Depending on the clinic and documentation involved, our administrative support may include:
- clinic and professional credential review;
- organization of available product documentation;
- review of product name, strength, and supporting records for consistency;
- review of publicly available FDA and licensing information;
- identification of missing or conflicting documentation; and
- communication support between the clinic and the appropriately licensed parties involved.
This gives clinic teams a more organized point of contact without shifting prescribing, pharmaceutical distribution, or clinical responsibilities to Phoenix Meds.
Who We Support
Phoenix Meds Inc. works with licensed U.S. healthcare organizations and medical leadership teams that need administrative support around product documentation and coordination.
This may include:
- physician-led medical practices;
- specialty medical clinics;
- licensed healthcare organizations;
- medical directors and physician groups; and
- clinic administration and operations teams.
Our services are business-to-business and intended for appropriately licensed U.S clinics and healthcare organizations.
Tesamorelin Administrative Coordination for Licensed Clinics
Licensed healthcare organizations may contact Phoenix Meds Inc. for administrative support involving tesamorelin documentation, professional credentials, product identity, and publicly available regulatory information. A coordination inquiry is not a medication order and does not itself establish product availability, clinical appropriateness, or regulatory eligibility.
Clinic Verification
Licensed healthcare organizations may submit relevant professional and facility credentials for administrative review.
Coordination Review
Phoenix Meds helps organize the available product information, supporting documentation, and relevant regulatory records and identifies items that may require clarification.
Licensed Parties
Prescribing, dispensing, distribution, storage, shipping, patient counseling, and other regulated pharmaceutical or clinical activities remain with the appropriately licensed parties responsible for those functions.
Frequently Asked Questions
What does Phoenix help clinics with when reviewing tesamorelin?
Phoenix Meds provides administrative coordination connecting licensed US clinics with licensed parties and may include documentation support.
Is tesamorelin FDA approved?
FDA has licensed specific tesamorelin biological products marketed as EGRIFTA SV and EGRIFTA WR. FDA’s Purple Book currently lists EGRIFTA SV 2 mg and EGRIFTA WR 11.6 mg under BLA 022505. That licensed status should not automatically be attributed to a different preparation marketed simply as “tesamorelin.”
What is EGRIFTA WR indicated for?
Current labeling identifies EGRIFTA WR for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. The labeling states that it is not indicated for weight-loss management.
Is tesamorelin 10 mg the same as EGRIFTA?
Not based on strength alone. FDA currently lists EGRIFTA SV at 2 mg and EGRIFTA WR at 11.6 mg. A product described as “tesamorelin 10 mg” should therefore be reviewed against its actual labeling and supporting documentation rather than assumed to be an EGRIFTA product.
Are EGRIFTA SV and EGRIFTA WR interchangeable?
No. Current labeling states that the formulations have different dosage, preparation, and storage requirements and are not substitutable.
Can Phoenix Meds help review product documentation?
Yes. Phoenix can help organize available documentation and identify missing, inconsistent, or unclear information that should be addressed by the responsible licensed party.
Does Phoenix prescribe or dispense tesamorelin?
No. Phoenix does not prescribe, manufacture, compound, dispense, sell, distribute, ship, or take custody of medications.
Does Phoenix provide dosing or treatment protocols?
No. Diagnosis, prescribing, dosing, administration, monitoring, and other patient-specific clinical decisions remain with the treating licensed healthcare professional.
Important Notice
Phoenix Meds Inc. provides administrative coordination, documentation support, and compliance-focused services for licensed healthcare organizations.
We are not a pharmacy, medical practice, manufacturer, outsourcing facility, compounder, wholesaler, distributor, prescriber, or dispensing entity. Clinical decisions and regulated pharmaceutical activities remain with the appropriately licensed parties responsible for those functions.
Regulatory References
- EGRIFTA — Product Details, BLA 022505
- EGRIFTA WR (Tesamorelin) — Current U.S. Prescribing Information
- EGRIFTA SV (Tesamorelin) — U.S. Prescribing Information
- Compounding and the FDA: Questions and Answers
- Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application